LifeSci Capital Begins Coverage Of Aradigm To Address Non-Cystic Fibrosis Bronchiectasis

LifeSci Capital Begins Coverage Of Aradigm To Address Non-Cystic Fibrosis Bronchiectasis

LifeSci Capital, LLC, a research-driven investment bank with proven experience and expertise in the field of life sciences sector recently announced the initiation of coverage for Aradigm. Aradigm is currently advancing inhaled ciprofloxacin antibiotics to better address chronic management of severe respiratory illnesses with particular attention on non-cystic fibrosis bronchiectasis (BE).

In 2014, Aradigm launched 2 Phase III trials, ORBIT-3 and ORBIT-4, to assess both efficacy and safety of their lead candidate Pulmaquin in 510 patients (255 individuals enrolled in each trial) suffering with non-CF bronchiectasis. The experimental drug is an inhaled liposomal formulation of ciprofloxacin that is taken once per day. The company now intends to wrap up the studies around June, 2016 and report data immediately after.

Pulmaquin might be particularly effective in treating BE patients because of its proven activity against Pseudomonas, (the bacteria responsible for the more severe forms of BE). Inhaled antibiotics tend to fail in the treatment of BE since the patients’ lungs are very sensitive. Data show that Lipoquin and Pulmaquin can safely deliver ciprofloxacin into the lungs without causing wheezing, cough or bronchoconstriction reactions frequently observed when antibiotics such as Tobi and Cayston are administrated.

LifeSci Capital in its report explained how Pulmaquin and Lipoquin can address the unmet medical need for non-CF bronchiectasis patients by reducing adverse lung reactions that use to result from inhaled antibiotics.

The LifeSci research team is under the leadership of Jerry Isaacson, who has proven experience in biotechnology and has worked before in both private and public biotechnology companies in a wide range of fields including medicinal, analytical chemistry, chemistry and others. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

LifeSci Capital offers services as an investment bank to support life science companies in order for them to discover, advance and commercialize innovative products. The company offers a deep understanding of their clients’ businesses. For more information, access the company’s website,